We leverage our experience in biopharmaceuticals and small molecules to develop, scale-up and optimize processes for Antibody-Drug Conjugates (ADCs) in support of both clinical and commercial manufacturing processes.
By leveraging our experience in biopharmaceuticals and small molecule drug process development and scale-up, we can manufacture high potency ADCs to support both clinical development and commercial manufacture of Antibody-Drug Conjugates (ADCs).
Unlike other contract development and manufacturing organizations (CDMOs) in the industry, we are in the unique position to offer:
- Complete development, optimization and manufacturing services for mammalian and microbial derived targeting agents
- Chemical synthesis of linkers and payloads
- Advanced conjugation technologies, process development, process optimization and BLA activities
- Formulation development (liquid and lyophilized) and drug product development
- Regulatory consulting and submission writing
We have experience with a wide range of bioconjugation technologies including the synergistic pooling of large and small molecule manufacturing practices to achieve delivery. We can provide a tailored solution for you to minimize risk, time cost and supply chain complexity.